ArticleDrug design, development and therapy2025
Danggui Buxue Decoction Alleviates Acute Hypoxia-Induced Sleep Disorders: Insights from in vivo and in silico Analyses.
Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Hypoxia-Induced Gut-Brain Axis Remodeling and Insomnia: Mechanisms and Microbiota Adaptive Regulation from a Translational Perspective.Journal of inflammation research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute hypoxia-induced sleep disorders (AHISD) frequently occur in individuals exposed to high altitudes, yet current treatment options are limited. Danggui Buxue decoction (DBD) originated from the ancient medical book "NeiWaiShangBianHuo Lun" for more than 700 years, and is widely used to treat anemic diseases in clinical, with the potential to treat AHISD. Methods: We employed a combination of behavioral assays, transcriptomics, neurotransmitter profiling, and in-silico approaches to evaluate the effects and mechanisms of DBD. Results: DBD supplementation significantly alleviated sleep disorders in AHISD fruit flies, restoring the sleep time and the sleep structure. Mechanistically, DBD alleviated AHISD mainly by restoring neurotransmitter balance such as Glutamine (Gln) and Glutamic acid (Glu), modulating serotonin receptors (5-HT1A/1B), and suppressing neuroinflammatory Toll and Imd pathways. In addition, resveratrol, magnolol, and caffeic acid as the main active ingredients of DBD played an important role in alleviating AHISD. Conclusion: These findings suggest DBD as a promising candidate for mitigating AHISD through neuroprotective and anti-inflammatory mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.